CN110035751A - 一种维利帕尼缓控释药物组合物及其用途 - Google Patents

一种维利帕尼缓控释药物组合物及其用途 Download PDF

Info

Publication number
CN110035751A
CN110035751A CN201780075192.4A CN201780075192A CN110035751A CN 110035751 A CN110035751 A CN 110035751A CN 201780075192 A CN201780075192 A CN 201780075192A CN 110035751 A CN110035751 A CN 110035751A
Authority
CN
China
Prior art keywords
release
wei lipani
sustained
weight
wei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780075192.4A
Other languages
English (en)
Inventor
甘勇
孟冰雪
郭仕艳
朱春柳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Science Rainbow Biopharma Co ltd
Original Assignee
Science Rainbow Biopharma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science Rainbow Biopharma Co ltd filed Critical Science Rainbow Biopharma Co ltd
Publication of CN110035751A publication Critical patent/CN110035751A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种维利帕尼口服缓控释药物组合物，该组合物包含溶出改善形式的维利帕尼和释放速率调节用基质聚合物。本发明的药物组合物可通过调控维利帕尼的体外释药行为调控维利帕尼于体内的吸收速率和吸收时间，进而精确地调控维利帕尼于体内的血药浓度水平及血药浓度波动范围，以高效持久地发挥维利帕尼对体内PARP酶的抑制活性，进而提高药物治疗效果，并降低药物毒副作用。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780075192.4A 2016-12-16 2017-12-15 一种维利帕尼缓控释药物组合物及其用途 Pending CN110035751A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611168720.4A CN108201535A (zh) 2016-12-16 2016-12-16 一种维利帕尼缓控释药物组合物及其用途
CN2016111687204 2016-12-16
PCT/CN2017/116472 WO2018108151A1 (zh) 2016-12-16 2017-12-15 一种维利帕尼缓控释药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN110035751A true CN110035751A (zh) 2019-07-19

Family

ID=62558007

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611168720.4A Pending CN108201535A (zh) 2016-12-16 2016-12-16 一种维利帕尼缓控释药物组合物及其用途
CN201780075192.4A Pending CN110035751A (zh) 2016-12-16 2017-12-15 一种维利帕尼缓控释药物组合物及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201611168720.4A Pending CN108201535A (zh) 2016-12-16 2016-12-16 一种维利帕尼缓控释药物组合物及其用途

Country Status (2)

Country Link
CN (2) CN108201535A (zh)
WO (1) WO2018108151A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110037993A (zh) * 2019-04-24 2019-07-23 康赋葆(深圳)生物医药科技有限公司 一种人参皂苷纳米缓释片的组成及制备方法
CN110013466B (zh) * 2019-05-28 2021-11-30 天津中医药大学 一种小檗红碱固体分散体粉末及制备方法及应用
TW202408509A (zh) * 2022-07-14 2024-03-01 大陸商西藏海思科製藥有限公司 雜芳基衍生物的藥物組合物及其在醫藥上的應用
CN115844856B (zh) * 2023-01-06 2023-05-16 北京中科利华医药研究院有限公司 一种双环醇固体制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311624A1 (en) * 2009-04-17 2011-12-22 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CN103417505A (zh) * 2012-05-24 2013-12-04 中国科学院上海药物研究所 具有双相释药行为的石杉碱甲控释制剂及其制备方法
CN105457038A (zh) * 2015-11-09 2016-04-06 东南大学 一种速释型药物磷脂化合物及其药物组合物
US20160206615A1 (en) * 2013-08-27 2016-07-21 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
WO2017136330A1 (en) * 2016-02-01 2017-08-10 Abbvie Inc. Extended release formulations of veliparib for the treatment of cancer
EP3275434A1 (en) * 2016-07-27 2018-01-31 Sandoz Ag An extended release oral dosage form

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873457A (zh) * 2009-06-02 2015-09-02 陶氏环球技术有限责任公司 缓释剂型
CN103040725B (zh) * 2012-12-26 2015-01-21 武汉九珑人福药业有限责任公司 一种利用研磨改善屈螺酮溶出的方法及屈螺酮固体分散体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311624A1 (en) * 2009-04-17 2011-12-22 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CN103417505A (zh) * 2012-05-24 2013-12-04 中国科学院上海药物研究所 具有双相释药行为的石杉碱甲控释制剂及其制备方法
US20160206615A1 (en) * 2013-08-27 2016-07-21 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
CN105457038A (zh) * 2015-11-09 2016-04-06 东南大学 一种速释型药物磷脂化合物及其药物组合物
WO2017136330A1 (en) * 2016-02-01 2017-08-10 Abbvie Inc. Extended release formulations of veliparib for the treatment of cancer
EP3275434A1 (en) * 2016-07-27 2018-01-31 Sandoz Ag An extended release oral dosage form

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHERRIE K. DONAWHO等: "ABT-888, an OrallyActive Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models", 《CLIN CANCER RES》 *
CLINICALTRIALS: "A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors", 《HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT01853306》 *
JOSE A MUNOZ-GAMEZ等: "Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles", 《LIVER INTERNATIONAL》 *
NAEL M. MOSTAFA等: "A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors", 《CANCER CHEMOTHER PHARMACOL》 *
RAJENDAR K. MITTAPA等: "Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation", 《PHARM RES》 *
THERESA LOUISE WERNER等: "Veliparib (ABT-888) extended-release formulations: A phase 1 study on safety, pharmacokinetics (PK), and bioavailability in patients with advanced solid tumors", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Also Published As

Publication number Publication date
CN108201535A (zh) 2018-06-26
WO2018108151A1 (zh) 2018-06-21

Similar Documents

Publication Publication Date Title
CN110035757B (zh) 一种奥拉帕尼口服缓控释药物组合物及其用途
US11096920B2 (en) Low-dose doxepin formulations and methods of making and using the same
JP5159303B2 (ja) 放出制御組成物
CN113573712A (zh) 尼洛替尼的药物组合物
CN110035744A (zh) 一种尼拉帕尼缓控释药物组合物及其用途
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
EP2057984B1 (de) Retardtabletten mit Hydromorphon
US20070128276A1 (en) Controlled release compositions comprising nimesulide
CN110035751A (zh) 一种维利帕尼缓控释药物组合物及其用途
JP2014528431A (ja) ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
US20050118266A1 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
CN108420798B (zh) 一种抗凝剂的速释药物制剂及其制备方法
CN108125918A (zh) 依维莫司药物组合物
EP3275434B1 (en) An extended release oral dosage form
CN103181886A (zh) 一种青蒿素或其衍生物的缓释制剂及其制备方法
JP2015516971A (ja) ざ瘡の処置方法
EP2547206A1 (en) Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
EP4205730A1 (en) Pharmaceutical composition of single dosage form for treating or preventing hypertension and hyperlipidemia
WO2018093289A1 (ru) Пероральная твердая лекарственная форма и способ ее получения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190719